A General Equilibrium Analysis of Achieving the Goal of Stable Growth by China's Market Expectations in the Context of the COVID-19 Pandemic

The COVID-19 pandemic triggered a weakening of expectations of market players and local governments. It is necessary to explore some effective paths to stabilize China's market expectations. This paper draws on computable general equilibrium (CGE) model elasticity indicators and marginal utility indicators to simulate the impact of the COVID-19 pandemic on market agents and the impact of shocks brought about by the COVID-19 pandemic on various industry sectors. Our results first show that the Keynesian closure is still valid, with the impact values of the COVID-19 pandemic on GDP, urban consumption, rural consumption, investment, imports, and exports being 2.35%, 7.96%, 9.79%, 4.10%, -3.13%, and 6.15%, respectively, with the COVID-19 pandemic shock having a particularly strong impact on rural consumption. Second, the impact of the COVID-19 pandemic on different industries is comprehensive and non-equilibrium. In consumption, urban and rural residents have the largest changes in consumption demand in the tertiary and primary industries, and the overall change in consumption of rural residents is larger than that of urban residents. In investment, the tertiary industry investment changes most significantly, while the primary industry has a gentle change. The impact of weaker import and export expectations on industry imports and exports is concentrated in the secondary and primary industries. Third, the weakening expectation induces a decline in the multiplier effect, making it difficult for economic growth to return to pre-pandemic levels, which needs to be accompanied by fiscal policies such as reducing taxes, lowering fees, and raising fiscal spending to achieve growth targets. In addition, while fiscal policy significantly boosts import and export trade, it has a significantly greater impact on exports than imports.

Mental distress, quality of life and physical symptoms in Chinese women with ovarian cancer receiving olaparib treatment during the COVID-19 pandemic.

Objectives: Women with ovarian cancer (OC) have experienced unprecedented challenges since the novel coronavirus disease-2019 (COVID-19) outbreak in China. We aim to evaluate the experience of psychological status, physical symptoms and quality of life (QoL) and investigate the impact of COVID-19 pandemic on OC patients receiving olaparib. Methods: The survey was conducted online from April 22 to May 12 in 2020. Demographic and clinical questions were listed to collect general information. The degree of insomnia, depression, anxiety, stress symptoms and QoL were assessed by the Chinese versions of the Insomnia Severity Index, the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7, the Impact of Event Scale-Revised, and the General Functional Assessment of Cancer Therapy, respectively. Multivariate logistic regression analysis was conducted to analyze the risk factors for mental distress and QoL. Results: A total of 56 respondents coming from 15 various provinces in China participated in the survey. The prevalence of insomnia, depressive, anxiety, stress symptoms and reduced QoL were 37.5, 51.8, 37.5, 30.4, and 51.8%, respectively. Unfavorable disease status, shorter period of olaparib administration, adverse events of olaparib and delay in cancer care were correlated with mental health problems. Reduced QoL was also significantly associated with psychological distress. Conclusions: This study emphasized that mental health problems and reduced QoL should gain more attention in women with OC who are receiving oral olaparib at home. Appropriate psychological healthcare strategies are necessary for OC patients during the COVID-19 pandemic.

Mental distress, quality of life and physical symptoms in Chinese women with ovarian cancer receiving olaparib treatment during the COVID-19 pandemic

Objectives Women with ovarian cancer (OC) have experienced unprecedented challenges since the novel coronavirus disease-2019 (COVID-19) outbreak in China. We aim to evaluate the experience of psychological status, physical symptoms and quality of life (QoL) and investigate the impact of COVID-19 pandemic on OC patients receiving olaparib. Methods The survey was conducted online from April 22 to May 12 in 2020. Demographic and clinical questions were listed to collect general information. The degree of insomnia, depression, anxiety, stress symptoms and QoL were assessed by the Chinese versions of the Insomnia Severity Index, the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7, the Impact of Event Scale-Revised, and the General Functional Assessment of Cancer Therapy, respectively. Multivariate logistic regression analysis was conducted to analyze the risk factors for mental distress and QoL. Results A total of 56 respondents coming from 15 various provinces in China participated in the survey. The prevalence of insomnia, depressive, anxiety, stress symptoms and reduced QoL were 37.5, 51.8, 37.5, 30.4, and 51.8%, respectively. Unfavorable disease status, shorter period of olaparib administration, adverse events of olaparib and delay in cancer care were correlated with mental health problems. Reduced QoL was also significantly associated with psychological distress. Conclusions This study emphasized that mental health problems and reduced QoL should gain more attention in women with OC who are receiving oral olaparib at home. Appropriate psychological healthcare strategies are necessary for OC patients during the COVID-19 pandemic.